Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chuanpu Hu

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Anesthesiology|February 26, 2005
Variability of target-controlled infusion is less than the variability after bolus injectionChuanpu Hu, Damian J Horstman, Steven L Shafer
Journal of Pharmacokinetics and Pharmacodynamics|June 21, 2011
Bounded outcome score modeling: application to treating psoriasis with ustekinumabChuanpu Hu, Newman Yeilding, Hugh M Davis, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 18, 2011
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasisChuanpu Hu, Philippe O Szapary, Newman Yeilding, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 1, 2013
Latent variable indirect response modeling of categorical endpoints representing change from baselineChuanpu Hu, Zhenhua Xu, Alan M Mendelsohn, et al.
Journal of Clinical Pharmacology|September 5, 2014
Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's diseaseChuanpu Hu, Omoniyi Adedokun, Kaori Ito, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 21, 2014
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpointChuanpu Hu, Philippe O Szapary, Alan M Mendelsohn, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2018
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitisChuanpu Hu, Omoniyi J Adedokun, Liping Zhang, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2026
Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response AnalysesSebastiaan C Goulooze, Camille Vong, Chuanpu Hu, et al.
Journal of Clinical Pharmacology|March 27, 2018
Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid ArthritisYan Xu, Chuanpu Hu, Yanli Zhuang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 17, 2010
A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexateChuanpu Hu, Zhenhua Xu, Mahboob U Rahman, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Anesthesiology|February 26, 2005
Variability of target-controlled infusion is less than the variability after bolus injectionChuanpu Hu, Damian J Horstman, Steven L Shafer
Journal of Pharmacokinetics and Pharmacodynamics|June 21, 2011
Bounded outcome score modeling: application to treating psoriasis with ustekinumabChuanpu Hu, Newman Yeilding, Hugh M Davis, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 18, 2011
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasisChuanpu Hu, Philippe O Szapary, Newman Yeilding, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 1, 2013
Latent variable indirect response modeling of categorical endpoints representing change from baselineChuanpu Hu, Zhenhua Xu, Alan M Mendelsohn, et al.
Journal of Clinical Pharmacology|September 5, 2014
Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's diseaseChuanpu Hu, Omoniyi Adedokun, Kaori Ito, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 21, 2014
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpointChuanpu Hu, Philippe O Szapary, Alan M Mendelsohn, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2018
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitisChuanpu Hu, Omoniyi J Adedokun, Liping Zhang, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2026
Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response AnalysesSebastiaan C Goulooze, Camille Vong, Chuanpu Hu, et al.
Journal of Clinical Pharmacology|March 27, 2018
Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid ArthritisYan Xu, Chuanpu Hu, Yanli Zhuang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 17, 2010
A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexateChuanpu Hu, Zhenhua Xu, Mahboob U Rahman, et al.
Pageof 6